# Biphasic Insulin Aspart Versus NPH Plus Regular Human Insulin in Type 2 Diabetic Patients

Study · id `cardio:ct-nct01889095` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01889095](<https://clinicaltrials.gov/study/NCT01889095>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01889095

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 160 participants.

## Technical summary

Registry record NCT01889095. Randomized; single masking; primary purpose treatment. Start 2011-07 (registry gives no type); primary completion 2011-08 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 160 participants (enrolled count; ClinicalTrials.gov record NCT01889095, source copy `cardio:ctgov-nct01889095-2013-06-28`, retrieved 2026-10-26)
- Start date: 2011-07 (registry gives no type) (ClinicalTrials.gov record NCT01889095, source copy `cardio:ctgov-nct01889095-2013-06-28`, retrieved 2026-10-26)
- Primary completion: 2011-08 (actual) (ClinicalTrials.gov record NCT01889095, source copy `cardio:ctgov-nct01889095-2013-06-28`, retrieved 2026-10-26)
- Completion: 2012-07 (actual) (ClinicalTrials.gov record NCT01889095, source copy `cardio:ctgov-nct01889095-2013-06-28`, retrieved 2026-10-26)
- Countries: Iran (ClinicalTrials.gov record NCT01889095, source copy `cardio:ctgov-nct01889095-2013-06-28`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01889095-2013-06-28`, retrieved 2026-10-26)

## The registry's words

- Brief title: Biphasic Insulin Aspart Versus NPH Plus Regular Human Insulin in Type 2 Diabetic Patients
- Condition: Diabetes Type 2
- Intervention (Drug): BIAsp 30
- Intervention (Drug): NPH/Reg
- Lead sponsor: Tehran University of Medical Sciences
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Tehran University of Medical Sciences (`cardio:org-tehran-university-of-medical-sciences`)

## Provenance

Content hash: 76203508cfb87ea3955988d1bdc75bfe74751d7d8766dd6e83d5283bff221512
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
